umirolimus

sirolimus derivative from a biodegradable polylactic acid polymer; possesses enhanced anti-inflammatory and antiproliferative activity with an improved pharmacokinetic profile; structure in first source

Also Known As:

Networked: 16 relevant articles (2 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Morice, Marie-Claude: 6 articles (07/2018 - 06/2009)
2.	Urban, Philip: 5 articles (07/2018 - 11/2015)
3.	Copt, Samuel: 3 articles (07/2018 - 01/2017)
4.	Richardt, Gert: 3 articles (07/2018 - 11/2015)
5.	Stoll, Hans-Peter: 3 articles (07/2018 - 11/2015)
6.	Talwar, Suneel: 3 articles (01/2018 - 11/2015)
7.	Abizaid, Alexandre: 2 articles (01/2020 - 11/2015)
8.	Fabbiocchi, Franco: 2 articles (01/2020 - 01/2018)
9.	Windecker, Stephan: 2 articles (01/2020 - 01/2014)
10.	Berland, Jacques: 2 articles (07/2018 - 11/2015)

Related Diseases

1.	Hemorrhage 07/20/2018 - "Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial." 01/01/2017 - "The randomized controlled LEADERS FREE (A Randomized Clinical Evaluation of the BioFreedom™ Stent) trial demonstrated the superior safety and efficacy of a polymer-free biolimus A9 DCS compared with a similar BMS used with 1 month of dual antiplatelet therapy in 2,466 patients at high bleeding risk. " 06/01/2021 - "Real-world analysis of a Biolimus A9 polymer-free drug-coated stent with very short dual antiplatelet therapy in patients at high bleeding risk." 01/01/2018 - "Two-year outcomes of high bleeding risk patients with acute coronary syndrome after Biolimus A9 polymer-free drug-coated stents: a LEADERS FREE substudy." 01/01/2020 - "In an international, randomized, single-blind trial, we compared polymer-based zotarolimus-eluting stents with polymer-free umirolimus-coated stents in patients at high bleeding risk. "
2.	Coronary Artery Disease (Coronary Atherosclerosis) 01/01/2012 - "Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects." 04/01/2011 - "The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study." 12/01/2008 - "The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study." 04/01/2011 - "To date, the pharmacokinetics of Biolimus A9 in patients following the deployment of BioMatrix II stents has not yet been studied BioMatrix II stents were implanted into 27 patients with coronary artery disease. " 12/01/2012 - "Biodegradable polymer eluting stents, such as the biolimus A9 eluting stent showed non-inferiority to durable polymer sirolimus eluting stent and, by reducing the risk of cardiac events associated with very late stent thrombosis, might improve long-term clinical outcomes in a variety of patients including chronic stable coronary artery disease and acute coronary syndromes. "
3.	ST Elevation Myocardial Infarction 01/01/2014 - "Individual patient data for 2,665 STEMI patients enrolled in 2 large-scale randomized clinical trials comparing newer-generation DES with BMS were pooled: 1,326 patients received a newer-generation DES (everolimus-eluting stent or biolimus A9-eluting stent), whereas the remaining 1,329 patients received a BMS. " 04/08/2016 - "STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical coherence tomography in patients with STEMI, NSTEMI and stable/unstable angina undergoing everolimus vs. biolimus A9-eluting stent implantation): a randomised controlled trial." 10/01/2023 - "The aim of the study was to compare healing (assessed by optical coherence tomography [OCT]) of biolimus A9 (BES) and everolimus drug-eluting stents (EES) at 9-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). "
4.	Unstable Angina 04/08/2016 - "STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical coherence tomography in patients with STEMI, NSTEMI and stable/unstable angina undergoing everolimus vs. biolimus A9-eluting stent implantation): a randomised controlled trial."
5.	Non-ST Elevated Myocardial Infarction 04/08/2016 - "STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical coherence tomography in patients with STEMI, NSTEMI and stable/unstable angina undergoing everolimus vs. biolimus A9-eluting stent implantation): a randomised controlled trial."

Related Drugs and Biologics

1.	Polymers
2.	Metals
3.	Everolimus
4.	zotarolimus
5.	BES
6.	Sirolimus (Rapamycin)
7.	poly(lactide) (polylactic acid)
8.	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))

Related Therapies and Procedures

1.	Stents
2.	Drug-Eluting Stents
3.	Therapeutics
4.	Percutaneous Coronary Intervention